Lipoprotein lipase Activatoor NO-1886 / 中国药理学通报

ABSTRACT

NO-1886 increases LPL mRNA and LPL activity in adipose tiss ue, myocardium and skeletal muscle, resulting in an elevation of postheparin pl asma LPL activity and LPL mass in rats. NO-1886 also decreasess plasma TG con centration and causes a concomitant rise in plasma HDL-C, reduces plasma gluco se, improves insulin resistance and ?-cell dysfunction. Therefore, the LPL act ivator NO-1886 or other possible LPL activating agents are potentially benefici al for the treatment of hypertriglyceridemia, hypo-HDL cholesterolemia, and pro tection from atheroscleroosis and diabetes.